The global peripherally inserted central catheter market are expected to be approximately USD 1,066.4 million in 2025 and is likely to expand up to approximately USD 1,391.9 million by the end of 2035. The sales are believed to rise with a CAGR of 2.7% during the period of 2025-2035.
Peripherally inserted central catheter produced revenue worth approximately USD 1,037.0 million in 2024.Peripherally Inserted Central Catheter market is expected to increase as the increased rate of long-term intravenous therapy needed in chronic illness like cardiovascular disease, cancer and other infection grows.
The market will increase due to innovation in catheter design, reducing the risk of thrombosis and improving patient comfort. Home infusion therapy and outpatient treatment transitioning will also contribute to driving demand because healthcare systems want to reduce the costs of hospitalization.
Businesses will focus on manufacturing catheters with fewer risks of infection and improved insertion techniques to prevent complications like occlusions and bloodstream infections. Product development will be driven by regulatory pressure, as tighter safety measures motivate companies to spend on biocompatible coatings and antimicrobial treatment.
High-growth opportunities in emerging economies in Asia and Latin America will be driven by increasing access to healthcare. Up to 2035, the market will witness a transition towards patient-centered solutions balancing cost reduction with safety and catheter long-term performance.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 1,066.4 million |
| Industry Value (2035F) | USD 1,391.9 million |
| CAGR (2025-2035) | 2.7% |
In the last few years, the PICC industry has witnessed tremendous change influenced by changing healthcare priorities, regulatory reforms and technological innovations.
The prevalence of chronic illnesses particularly cancer and infectious diseases which need ongoing drug treatment has driven increased utilization of PICCs as an efficient and reliable alternative for long-term intravenous administration as a cost-saving and reliable option for long-term intravenous therapy.
In addition, expansion in home healthcare provisions further increased demand since patients and hospitals seek alternatives that reduce healthcare expenses and inpatient days. One of the most important developments has been increasing focus on reducing catheter-associated complications that include bloodstream infection and thrombosis.
Additionally, advances in catheter insertion methods which utilizes ultrasound-guided placements have yielded greater success and reduced procedural complications. Reimbursement policies have influenced purchasing decisions in developed economies by promoting cost-efficient, long-lasting products. Asian-Pacific and Latin American markets have quicker market penetration and attained through increasing healthcare access and medical infrastructure investments.
Explore FMI!
Book a free demo
North America is expected to maintain a dominating share in the global PICC market owing to a rapid adoption of advanced catheterization procedures and growing cases of chronic diseases necessitating long-term intravenous therapy. The existence of international market players and continuous research and development activities is further driving growth.
In addition, the extensive focus on infection control practices and the use of antimicrobial coated PICCs are likely to enhance patient safety. The United States holds the maximum revenue share in North America, due to its strong healthcare infrastructure, rising in-patient cases that needs long term IV therapy and beneficial reimbursement policies.
Increased outpatient care and home healthcare services are also fueling demand for PICCs in the region. Streamlining regulatory processes and enhancing training programs for healthcare workers are anticipated to offset some of the challenges associated with PICC placement and maintenance.
Europe is expected to witness a stable growth, led by a strong focus on patient safety, increasing healthcare spending and government programs aiming at enhancing vascular access management. Germany, UK and France leads the market in adopting advanced PICC insertion procedures in end user facilities.
Increased use of antimicrobial and heparin-coated catheters is improving patient outcomes and minimizing complications which is contributing to the market growth. Furthermore, technological advancement in catheters which includes power injectable PICCs and valve integrated systems are enhancing the effectiveness of the treatment.
The European market is also gaining prominence from collaboration and partnerships between healthcare providers and medical device manufacturers to improve PICC safety standards. The differences in healthcare policies and reimbursement schemes in each of these European countries may pose a challenge towards market penetration.
The Asia-Pacific region will be the region with high growth in the PICC market. With growth through rising investment in healthcare infrastructure and expanding prevalence of chronic illnesses in key countries. China, India, and Japan key countries holding significant share of the market and are experiencing significant growth in hospital settings as well as home care services, fueling growing demands for PICCs.
The increase in non-communicable conditions with a focus on cancer and chronic infection needing long-term intravenous therapy which is driving adoption of this market further.
In spite of robust growth opportunities, market access in certain countries is hindered by restricted access and a paucity of trained specialists in PICC placement and management. Governments are aggressively encouraging healthcare development by revolutionizing policy initiatives and funding programs enhancing the availability of cost-effective PICC solutions.
In order to ensure sustainable growth, investment in training medical personnel and enhanced access to high-quality disposable medical devices continues to be crucial.
Risk of Catheter Based Infections and Complications
One of the major challenges of the peripherally inserted central catheter market is catheter-related bloodstream infection and thrombosis and occlusion. Infections have remained a major risk despite advancements in the materials of catheters particularly among high-risk patients such as those undergoing chemotherapy or long-term antibiotic therapy.
Health care providers and hospitals are required to put in rigorous infection prevention practices which includes proper catheters maintenance, sterile dressing and observation of accurate vascular access care practice. Furthermore, the availability of antimicrobial-coated and heparin-impregnated PICCs has reduced risks, there by leading to more expensive innovations.
The necessity for ongoing education of healthcare workers is best practice in PICC management as improper handling and care increases the risk of infection, producing prolonged hospital stays, increased treatment cost and worse patient outcomes.
Limited Access to Skilled Healthcare Professionals
Successful placement and management of PICCs need highly trained healthcare professional. Shortage of trained nurses and interventional radiologists with experience in vascular access procedures is a challenge to this field. In hospital settings, PICC insertion is still performed by general practitioners or untrained nurses, thereby raising the prevalence of complications such as misplacement, vein perforation, and catheter malfunction.
Most medical professionals working in low and middle income countries lack hands-on practice on sophisticated catheter technologies and infection-prevention best practices. To address such circumstances, producers have to invest in nursing and doctor training programs encouraging certification courses and enabling simulation education.
Expansion of Home Healthcare and Outpatient Infusion Therapy
The increasing shift towards home healthcare and outpatient infusion therapy creates a huge opportunity for the Peripherally Inserted Central Catheter market. With escalating healthcare expenses, payers and hospitals are focusing on inpatient alternatives which translates into higher demand for PICCs in intravenous therapy at home.
Chronic condition patients like cancer, infections along with autoimmune disorders benefit from extended intravenous treatment, and for such safe and efficient drug administration in non-healthcare settings.
The growth in remote patient monitoring also complements this trend by allowing clinicians to monitor PICC maintenance and manage complications without frequent hospital visits. Medical device companies are also creating easy-to-use and self-administrable PICC products to improve patient compliance and decrease dependence on healthcare workers.
This trend not only enhances patient comfort but also lowers hospital-acquired infections and total healthcare costs considerably, making it a major driver of growth.
Biodegradable and Bioabsorbable PICCs
Development of biodegradable and bioabsorbable peripherally inserted central catheters is a revolutionary possibility in vascular access devices. Traditional PICCs, while effective for long-term intravenous treatment are inconvenient, uncomfortable inducing irritation or infection of the vein.
Biodegradable PICCs promise to overcome this by degrading naturally in the body over time, obviating the need for removal and risk of catheter-related complications. One of the main driving forces behind bioabsorbable PICCs is the desire for increased patient safety and comfort. Such catheters must be made from state-of-the-art polymer materials that have the capability to reduce thrombosis risk and minimize biofilm formation.
In addition, regulatory agencies are now giving more emphasis to innovations that lead to improved patient outcomes and bioabsorbable PICCs fit these objectives. Future growth can also be expected from the Asia-Pacific region and Latin America regions as these regions demands for cost-saving and low-maintenance vascular access devices.
From 2020 to 2024, the peripherally inserted central catheter market grew steadily due to the rising prevalence of chronic conditions, rising hospitalization rates and technology improved catheter materials and designs. The increasing demand for long-term intravenous therapy, especially in oncology and critical care settings have fueled market growth.
Enhanced catheter placement methods and infection control practices improved patient safety and procedural effectiveness. But complications like thrombosis and catheter-related infections created issues and thus demanding ongoing innovation in product development.
Entering 2025 to 2035, the market will be influenced by continuing improvements in antimicrobial coating technology, usage of bioresorbable materials and also improving catheter navigation technologies. The use of real-time imaging for accurate placement and the evolution of home PICC care solutions will improve patient outcomes and access. Regulatory policy will also focus on infection prevention protocols.
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Focus on prevention of infection and patient safety, with region-dependent approval procedures for novel catheter design |
| Technological Advancements | Development of antimicrobial-coated and power-injectable PICCs for reducing infection risk and improving procedural success |
| Consumer Demand | Growing utilization in oncology, critical care, and home healthcare settings due to rising chronic disease burden |
| Market Growth Drivers | Rising prevalence of chronic illnesses and growth in outpatient and home-based care, and advances in catheter technology |
| Sustainability | Limited focus on sustainability, with emphasis on sterility and performance. |
| Supply Chain Dynamics | Supply chain disruptions affected availability, with dependency on specialized producers for catheter parts |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Stringent global regulation on antimicrobial efficacy and sustainable catheter materials |
| Technological Advancements | Imaging with AI-based guidance for placement, biodegradable catheters, and smart monitoring devices for remote care |
| Consumer Demand | Growing need for home infusion therapy and patient-specific catheter solutions according to individual patient requirements |
| Market Growth Drivers | Technological innovation, enhanced infection control measures and greater accessibility to PICC services in developing markets. |
| Sustainability | Increased relevance of eco-friendly materials, recyclable packaging in manufacturing practices and compliance with global standards |
| Supply Chain Dynamics | Enhanced supply chain resilience through regional production centers and raw material sourcing diversification |
Market Outlook
The peripherally inserted central catheter market in the United States is experiencing steady growth primarily driven by increasing prevalence of chronic diseases such as cancer and cardiovascular disorders. The demand for long-term intravenous therapies necessitates reliable vascular access solutions, positioning PICCs as a preferred choice of IV therapy among healthcare professionals.
Technological advancements and a well-established healthcare infrastructure further support market expansion with the inaugural of many new cancer hospitals and stand-alone chemotherapy and infusion center for drug delivery.
Additionally, the increasing adoption of home healthcare services is boosting the use of PICCs for outpatient treatments.
The federal government and private healthcare facilities are investing in infection prevention strategies making PICC with antimicrobial coatings more attractive. As hospitals shift towards cost-efficient and patient-friendly treatment approaches, the PICC market is expected to grow further.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 5.8% |
Market Outlook
The sales for peripherally inserted central catheters in Germany is growing due to its strong healthcare system. With increasing preference for minimally invasive procedures towards the treatment of chronic diseases contribute to a large extent to the growing penetration of PICCs in this country. The focus on infection control and patient safety also boosts market growth. Germany has one of the most advanced medical facilities in Europe with high-quality vascular access solutions that assures a steady demand.
The major medical device suppliers presence combined with ongoing research is driving product innovation. Also, the increasing in-patient admissions requiring long-term medical therapies, is driving demand for safe and effective vascular access devices.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 4.4% |
Market Outlook
Peripherally inserted central catheters market in India is expected to grow substantially fueled by growing healthcare facilities in Indian sub-continent and increased shift towards sophisticated treatments modalities.
The rising chronic diseases cases with different disease indication demands for cost-effective and long-term treatment solutions which is expected to drive the growth of this market. India’s healthcare industry has transformed at a faster pace with private hospitals and medical centers embracing sophisticated vascular access technologies.
There is a significant rise in the demand for PICCs interventions in cancer cases with chemotherapy treatments becoming increasingly prevalent in urban as well as rural regions. Government efforts to enhance cancer treatment centers are also driving the demand for PICC in India market.
Also, an increase in hospital-acquired infections has always been a cause of concern and prompted towards creation of safer catheter technologies, with companies concentrating on antimicrobial and biocompatible PICC solutions. As India emerging as a significant medical tourism destination, the need for quality products will definitely increase in the future.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 6.9% |
Enhancing Efficiency in High-Pressure Power Injections
Power Injected PICCs lead the market with a significant market share due to its demand in contrast-enhanced imaging studies. These catheters facilitate quick delivery of contrast media during medical imaging procedures and thus enhancing diagnostic precision.
Their strength and compatibility with a range of infusion therapies make them more favorable in hospitals and diagnostic imaging centers. In addition, improvements in catheter design and material which includes anti-thrombogenic coatings, improve patient safety and minimize complications related to long-term vascular access.
The need for power-injected PICCs has increased with the growing number of radiological procedures that need contrast media agents for image enhancement. Further, their ability to administer chemotherapy drugs and other medications makes them more competitive in the market. Hospitals, Imaging Centers and Standalone Infusion Centers are increasingly turning to these catheters due to their ease of use and effectiveness in lowering repeated access needle stick injuries.
Reliable and Widely Used for Long-term Access
Traditional PICCs retain a considerable market share due to the fact that they offer a cost-effective and viable option for patients that need long-term intravenous treatment. Apart from their usage in chemotherapy, they are also used for antibiotic therapy and parenteral nutrition. The penetration of this catheters home care settings are also key factors that have fueled demand for traditional PICCs.
Advancements in cathiagnostics imaging center and insertion methods have further bolster this segment growth. Unlike power-injected PICC, traditional PICC are generally preferred in environments constituting a long-term and consistent medication delivery.
The market for these devices is growing as healthcare providers are keen on shortening length of stay and moving towards outpatient and home healthcare services. In addition, advances in catheter coatings materials has improve patient outcomes by decreasing complications like bloodstream infections and thrombosis.
Long-term IV infusion and Chemotherapy Leading Application Due to Growing Cancer Prevalence
Long-term IV infusion and Chemotherapy still dominates the market for peripherally inserted central catheters, propelled by the growing cancer burden worldwide, widely used for intravenous antibiotic therapy, hydration and pain management in patients demands for safe and long-term vascular access.
PICCs provide a less invasive and efficient means of multiple chemotherapy infusions, minimizing repeated needle insertions. The growth in outpatient and home-based chemotherapy treatment is also driving market demand and increasing revenue sales.
Also, new catheter technologies, including antimicrobial surfaces and ultrasound guidance, improve procedural success and patient safety. PICCs are also increasingly becoming a popular option compared to standard central venous catheters because of the simplicity of insertion and lower complication rates.
With continuous research on targeted drug delivery and precision medicine, the need for chemotherapy-compatible PICCs will increase. Additionally, patient preference for less invasive procedures and enhanced catheter stabilization methods are favoring wider adoption in healthcare settings.
Dominance of Double Lumen PICCs
Double lumen peripherally inserted central catheters accounts for the largest market share, propelled by their utility in the simultaneous administration of various therapies. Double lumen PICCs enable the delivery of multiple drugs without risking drug incompatibility and hence becoming the treatment of choice in many indications in critical care settings.
Double lumen PICCs are widely used by hospitals and outpatient infusion centers to maximize the efficiency of treatment and minimize the number of vascular access sites.
The increasing incidence of cancer and sepsis in critical care settings, patients are need to be treated with intravenous therapy for extended periods using multiple drug regimens. With a notable increase in home healthcare services also drives adoption, these catheters reduce hospitalization rates by allowing administration of multiple medications at once in a single device, which provides greater convenience and compliance for patients.
The PICC market continues to expand, driven by technological advancements, increasing demand for long-term intravenous therapy solutions, and the growing prevalence of chronic diseases requiring extended vascular access.
The Peripherally Inserted Central Catheter (PICC) market is expanding steadily because of the surging demand for long-term intravenous access for chemotherapy, administration of antibiotics, and parenteral nutrition. Growth in the incidence of chronic diseases, innovation in catheter design, and growth in hospital admissions are major drivers of market growth.
Top companies are emphasizing product innovations, infection control strategies, and strategic alliances to enhance market presence. The market has traditional medical device manufacturers and niche players with more affordable and cutting-edge solutions.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Becton, Dickinson and Company (BD) | 25-30% |
| Cardinal Health Inc. | 15-20% |
| AngioDynamics, Inc. | 7-10% |
| Teleflex Incorporated | 5-10% |
| Other Companies (combined) | 40-30% |
| Company Name | Key Offerings/Activities |
|---|---|
| Becton, Dickinson and Company | Develops advanced PICC lines with antimicrobial coatings and improved safety features. |
| Teleflex Incorporated | Offers high-performance catheters with a focus on reducing infection risks. |
| AngioDynamics, Inc. | Specializes in vascular access solutions, including power-injectable PICC lines. |
| Cardinal Health Inc. | Provides cost-effective, high-quality PICC solutions with a strong global presence. |
Key Company Insights
Becton, Dickinson and Company (25-30%)
Becton, Dickinson and Company is a market leader in the PICC space, with a reputation for innovative catheter designs that improve patient safety and minimize complications. Its antimicrobial PICC lines are seen commonly in hospitals around the globe, and BD continues to invest in research and development to create next-generation vascular access devices.
Cardinal Health Inc. (15-20%)
Cardinal Health offers economical and high-quality PICC solutions with a great focus on easy-to-use designs and worldwide market presence. Cardinal Health continues to diversify its product lines through research and innovation.
AngioDynamics, Inc. (10-15%)
AngioDynamics provides power-injectable PICC lines that enable high-pressure contrast injections for imaging procedures. The company is dedicated to innovation in vascular access technology and increasing its presence in the global healthcare market.
Teleflex Incorporated (5-10%)
Teleflex specializes in high-performance PICC solutions that reduce the risk of infection and optimize procedural efficiency. Teleflex's Arrow® PICC portfolio is known for innovative catheter materials and simple insertion methods, thus being a favored option among healthcare professionals
Several other companies contribute to the PICC market by introducing innovative designs and expanding their distribution networks. Notable players include:
These companies focus on improving catheter safety, enhancing ease of insertion, and developing antimicrobial coatings to reduce infection risks. As competition intensifies, ongoing innovation and strategic partnerships will play a crucial role in shaping the future of the PICC market.
The global peripherally inserted central catheter industry is projected to witness CAGR of 2.7% between 2025 and 2035.
The global peripherally inserted central catheter industry stood at USD 1,037.0 million in 2024.
The global peripherally inserted central catheter industry is anticipated to reach USD 1,391.9 million by 2035 end.
China is expected to show a CAGR of 5.3% in the assessment period.
The key players operating in the global peripherally inserted central catheter industry are Becton, Dickinson and Company, Teleflex Incorporated, AngioDynamics, Inc., Cardinal Health Inc., Vygon Group, B. Braun Melsungen AG, ICU Medical, Inc., Cook Medical Incorporated, Argon Medical, Kimal Plc Utah Medical Products, Inc. and others
Stable Angina Management Market Analysis by Drug Class, Distribution Channel, and Region: Forecast for 2025 to 2035
Pet DNA Testing Market Analysis by Animal Type, Sample Type, Test Type, End User and Region: Forecast for 2025 to 2035
Panuveitis Treatment Market Analysis & Forecast by Drug Class, Route of Administration, Distribution Channel, and Region Through 2035
Phenylketonuria Therapeutics Market Analysis & Forecast by Drug Type, Route of Administration, Distribution Channel, and Region Through 2035
Dental Practice Management Software Market Growth, Demand & Forecast 2025 to 2035
Dental Consumables Market Insights by Product, End-Users, and Region through 2035
Peripherally Inserted Central Catheter Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
